Clinical Effect of Revascularization Strategies and Pharmacologic Treatment on Long-Term Results in Patients with Advanced Peripheral Artery Disease with TASC C and D Femoropopliteal Lesions

Figure 2

(a) Patients who received cilostazol treatment for more than 3 months had a better 3-year amputation-free survival (AFS) rate than patients who received treatment for fewer than 3 months (log rank test, ). (b) Patients receiving statin treatment had a superior 3-year AFS rate to those who did not receive treatment (log rank test, ). (c) Patients who presented with TASC D peripheral artery disease (PAD) had an inferior 3-year AFS rate than patients who had TASC B plus C PAD (log rank test, ). (d) Patients with diabetes mellitus had a poorer 3-year AFS rate than patients without DM (log rank test, ).

(a)

(b)

(c)

(d)